OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.

The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.

The acquisition brings closure for Mirati at last, though some investors will feel disappointed.